Neoadjuvant					
PI	**CRC**	**Protocol #/Title**	**Mechanism**	**Primary In/Ex Criteria**	**Status**
Mehta	Linda	UCI 14-67: A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting	HER-2 monoclonal antibody VEGF monoclonal antibody	Pathologically proven invasive breast cancer Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging) and/or with involved lymph node	Open to Accrual
Parajuli	Linda	UCI 18-02: A Phase II, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients with Early Triple-Negative Breast Cancer	PARP inhibitor	Locally advanced triple-negative adenocarcinoma of the breast, tumor > 1.5 cm Must have confirmation of germline BRCA 1/2 mutation (central or local w/ sponsor approval) Must have archive tumor tissue or undergo biopsy	Open to Accrual
Adjuvant					
PI	**CRC**	**Protocol #/Title**	**Mechanism**	**Primary In/Ex Criteria**	**Status**
Mehta	Linda	SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer	mTOR-inhibitor in addition to endocrine therapy	ER/PR +, HER2-, high-risk invasive breast carcinoma Patients must be registered within 42 weeks of last dose of chemo (standard neo-adjuvant or adjuvant)	Open to Accrual
Mehta	Linda	Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial	NSAID to improve invasive disease free survival (iDFS)	Patients (ages 18-70) with HER2 negative breast carcinoma and free of recurrence If ER/PR negative, must be registered within 18 mo of dx If ER/PR positive, must be registered within 10 yrs of dx Regular NSAID/Aspirin use at any dose (including baby aspirin) (defined as ≥ 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for 30 days prior to study entry and throughout the study period	Open to Accrual
Mehta	Linda	SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy	humanized Mab of the igG4/kappa isotype	Patients must have triple-negative breast cancer and not be planning to recieve adjuvant anti-HER2 or endocrine therapies after completion of neoadjuvant chemotherapy Residual disease must be ≥ 1 cm in greatest dimension, and/or have positive lymph nodes (ypN+) observed on pathologic exam	Open to Accrual
Daroui	Linda	Alliance A221505: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction	fractionated external radiation therapy	Patients must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 8 months after radiation.	Open to Accrual
Daroui	Linda	NSABP B51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Nega	chestwall and regional nodal radiation therapy	Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy).	Open to Accrual

Linda Vo 714-456-6264
Mehir Tharani 714-509-2643
Anabel Serwanska 714-456-8279
Oliver Quines 714-456-6244

Metastatic					
PI	**CRC**	**Protocol #/Title**	**Mechanism**	**Primary In/Ex Criteria**	**Status**
Parajuli	Linda	UCI 17-79: Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer	IgG1 monoclonal antbody binding to LIV-1 and linker in lysosomes releasing MMAE which prevents cell division.	Metastatic or locally-advanced triple-negative breast cancer Have not previously received therapy for the treatment	Open to Accrual
Parajuli	Linda	UCI 18-06: A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast can	Oral class I α-specific PI3K inhibitor to inhibit the proliferation of cell lines harboring PIK3CA mutations	HR+, HER2-, PIK3CA mutant advanced breast cancer (aBC) Documented evidence of tumor progression on or after CDK 4/6 inhibitor combination treatment; CDK 4/6 inhibitor must be the last treatment regimen prior to study entry. No more than 2 prior anti-cancer therapies for aBC	Open to Accrual
Daroui	Linda	BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer	SBRT	≤ 4 metastases seen on standard imaging within 60 days prior to registration when all metastatic disease is located within the peripheral or central lung, bone, spine, abdominal–pelvic(lymph node/adrenal gland), liver or mediastinal/cervical lymph node Patients must be registered within 365 days of the initial metastatic breast cancer diagnosis.	Open to Accrual
Bota	Mehir	UCI 16-74: A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a	topoisomerase-1inhibitor	Histologically-confirmed carcinoma of the breast with hx of brain mets that are non-progressing, must have been treated ≥ 14 days prior to randomization Measurable or non-measurable disease	Open to Accrual
Bota	Mehir	SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	anti-ctla4 mAb and anti-PD-1 mAb	Metaplastic carcinoma (of breast)	Suspended
Uchio	Phil Duffy/ Steven Bereta	UCI 18-101: A Phase 1 Dose Escalation Study Evaluationg Safety, Tolerability and Pharmacokinetics of PF-0695229 in Adult Patients With Advanced Solid Tumors	serine/theonine kinase receptor impacting growth and proliferation of malignancies	Patients must have progressed on prior CDK4/6 inhibitor therapy Patients must have received two or less prior lines of therapy in the metastatic setting	Pending Activation
Phase 1/Basket Trials					
PI	**CRC**	**Protocol #/Title**	**Mechanism**	**Primary In/Ex Criteria**	**Status**
Zhu	Anabel	UCI 18-19: An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies	PD-1 antagonist	Histologically or cytologically confirmed advanced/metastatic cancers with high Tumor Mutation Burden level	Open to Accrual
Zhu	Oliver	UCI 17-90: A Two-Part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients with HER2-Positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy	erbB TKI	Patients with HER2 positive metastatic breast cancer who have experienced disease progression after receiving at least 2 prior anti-HER2 therapies for metastatic disease that contain trastuzumab with or without pertuzumab, prior T-DM1, or lapatinib therapy is required	Open to Accrual
Bota	Linda	ECOG EAY131: Molecular Analysis for Therapy Choice (MATCH)	treatment based on mutation	Positive for Specific Mutations	Open to Accrual
Ou	Anabel	UCI 18-21: A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)	RET Receptor Tyrosine Kinase inhibitor that harbors RET alterations	Patient with RET fusion-positive solid tumor or an advanced solid tumor that harbors a RET gene alteration (excluding synonymous, frameshift, or nonsense mutation)	Open to Accrual

Linda Vo 714-456-6264
Mehir Tharani 714-509-2643
Anabel Serwanska 714-456-8279
Oliver Quines 714-456-6244

Non-Treatment Trials (Diagnostic/Screening/Basic Science)					
PI	**CRC**	**Protocol #/Title**	**Mechanism**	**Primary In/Ex Criteria**	**Status**
Feig	Wanda	Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer	MRI pre-surgery to determine lumpectomy vs. mastectomy	Patients may not have had an MRI of the breast within 12 months prior to registration. Patients must be suitable to undergo MRI with contrast agent dye gadolinium. Patients must have no bialteral breast cancer or previous invasive breast cancer or DCIS of the same breast.	Suspended
Anton-Culver	Andrea	UCI 16-23: Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM study (Women Informed to Screen Depending on Measures of Risk)]	risk based screening strategy	Patients must be between the ages of 40 to 74 years old. Patients must agree to receive breast screening at an Athena site (UCSF, UCSD, UCLA, UCI, or Standford).	Open to Accrual
Anton-Culver	Valerie	UCI 10-24: ATHENA Breast Health Network	Breast Screening	Patients have no history of mastecomy in both breasts Patients are between the ages of 40 - 74 years No history of breast cancer or DCIS	Open to Accrual
Daroui	Bianca	UCI 13-19: Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III Breast Cancer	Data collection	Patients treated with chemotherapy followed by Mastectomy	Open to Accrual
Nelson	Christopher	UCI 16-01: Pathway Analyses for Individualized Network Therapies for Cancer (PAINT)	Evaluating over 1200 gene products/transcripts from FFPE samples	Patients must have a histologically proven diagnosis of cancer. Have available formailin fixed paraffin embedded tumor sample.	Open to Accrual

Linda Vo 714-456-6264
Mehir Tharani 714-509-2643
Anabel Serwanska 714-456-8279
Oliver Quines 714-456-6244